Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

rovide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

-- Qualitative diagnosis and referral patterns for the United States

based on thought leader input and guideline recommendations.

-- Quantitative treatment algorithms based on patient-level claims data

Product share (class and specific compound level) within each line

of therapy (1st, 2nd, 3rd line).

-- Practicing physician opinion on why specific drugs are chosen for

certain patient populations.

-- Discussion of key drug combinations (including add versus switch

patterns) by lines of therapy.

-- Progression of therapy from key 1st line products (e.g., initial

treatment with Lipitor to 2nd line, 3rd line; initial treatment with

Zocor to 2nd line, 3rd line).

-- Pathway to key therapies from previous therapies (e.g., how much

Avandamet use is preceded by metformin, Avandia, or both as single

products?).

-- Qualitative analysis of 2-year forecast incorporating practicing

physician sentiment towards upcoming launches, changes in

reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information,
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... YORK , July 8 Bion Environmental Technologies, ... a public issues forum on July 14 , hosted ... Relations at their Campus Center auditorium.  The forum, sought by ... development group, will address Bion,s proposed beef cattle production facility ...
... Calif. , July 8 ... announced the completion of a Series A financing totaling ... with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures ...  The capital will be used to support the company,s ...
... ... interactive healthcare marketing at Digital Pharma West. , ... (PRWEB) -- Viscira™, a leading provider of interactive and ... Return on Interactive” at the Digital Pharma West (DPW) conference last week in San ...
Cached Biology Technology:Bion Confirms Participation in SUNY Oswego's Forum 2Bion Confirms Participation in SUNY Oswego's Forum 3Bion Confirms Participation in SUNY Oswego's Forum 4Calithera Biosciences Closes $40 Million in Series A Financing 2Calithera Biosciences Closes $40 Million in Series A Financing 3Calithera Biosciences Closes $40 Million in Series A Financing 4Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference 2
(Date:4/20/2014)... demonstrate a bizarre property never before seen at a ... scientists at the University of Cambridge. The property ... application as wide-ranging as soundproofing, super-absorbent sponges and bulletproof ... if one pulls on an elastic band, the elastic ... squeeze a material and it will expand for ...
(Date:4/20/2014)... used to treat lung, breast and pancreatic cancers also ... the University of California, San Diego School of Medicine ... the surface of drug-resistant tumors that appears responsible for ... of cancer cells. , The findings, published in ... Cell Biology , may point to new therapeutic opportunities ...
(Date:4/20/2014)... with Down syndrome have a heightened risk of developing ... able to explain why. Now, a team of ... the two conditions. , In a study posted online ... researchers track the genetic chain of events that links ... havoc that occurs in ALL. Their findings are ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... published by ASM Press educates the reader by focusing ... teaching virology for more than 35 years, Virology: Molecular ... understanding of fundamental virology by emphasizing principles and discussing ... Molecular Biology and Pathogenesis is meant to be used ...
... have found that the hydrodynamic environment of fish can shape ... the Journal of Experimental Biology Web site, was ... Dynamics. Catch a glimpse of a fish,s body shape, ... and mackerel look as if they should outpace frilly reef ...
... Mediterranean Sea has a stable and constant dolphin population off ... also consider the dolphins," says Dr. Aviad Scheinin of the ... commercial fishing endangers dolphin populations in the Mediterranean. This has ... University of Haifa,s Department of Maritime Civilizations. "Unfortunately, we turn ...
Cached Biology News:Virology text focuses on families 2Research finds water movements can shape fish evolution 2Commercial fishing endangers dolphin populations 2Commercial fishing endangers dolphin populations 3
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
96 Well Base Plate...
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
Biology Products: